PDF(Pubmed)
Abstract：
Understanding the effectiveness of novel models of care in community-based settings is critical to achieving hepatitis C elimination. We conducted an evaluation of a hepatitis C model of care with financial incentives that aimed to improve engagement across the hepatitis C cascade of care at a sexual health service in Cairns, Australia.
Between March 2020 and May 2021, financial incentives were embedded into an established person-centred hepatitis C model of care at Cairns Sexual Health Service. Clients of the Service who self-reported experiences of injecting drugs were offered an AUD 20 cash incentive for hepatitis C testing, treatment initiation, treatment completion, and test for cure. Descriptive statistics were used to describe retention in hepatitis C care in the incentivised model. They were compared to the standard of care offered in the 11 months prior to intervention.
A total of 121 clients received financial incentives for hepatitis C testing (antibody or RNA). Twenty-eight clients were hepatitis C RNA positive, of whom 92% (24/28) commenced treatment, 75% (21/28) completed treatment, and 68% (19/28) achieved a sustained virological response (SVR). There were improvements in the proportion of clients diagnosed with hepatitis C who commenced treatment (86% vs. 75%), completed treatment (75% vs. 40%), and achieved SVR (68% vs. 17%) compared to the pre-intervention comparison period.
In this study, financial incentives improved engagement and retention in hepatitis C care for people who inject drugs in a model of care that incorporated a person-centred and flexible approach.
Between March 2020 and May 2021, financial incentives were embedded into an established person-centred hepatitis C model of care at Cairns Sexual Health Service. Clients of the Service who self-reported experiences of injecting drugs were offered an AUD 20 cash incentive for hepatitis C testing, treatment initiation, treatment completion, and test for cure. Descriptive statistics were used to describe retention in hepatitis C care in the incentivised model. They were compared to the standard of care offered in the 11 months prior to intervention.
A total of 121 clients received financial incentives for hepatitis C testing (antibody or RNA). Twenty-eight clients were hepatitis C RNA positive, of whom 92% (24/28) commenced treatment, 75% (21/28) completed treatment, and 68% (19/28) achieved a sustained virological response (SVR). There were improvements in the proportion of clients diagnosed with hepatitis C who commenced treatment (86% vs. 75%), completed treatment (75% vs. 40%), and achieved SVR (68% vs. 17%) compared to the pre-intervention comparison period.
In this study, financial incentives improved engagement and retention in hepatitis C care for people who inject drugs in a model of care that incorporated a person-centred and flexible approach.
摘要：
背景：了解社区环境中新型护理模式的有效性对于消除丙型肝炎至关重要。我们对丙型肝炎护理模式进行了评估，该模式具有财务激励措施，旨在提高凯恩斯性健康服务机构对丙型肝炎级联护理的参与度，澳大利亚。
方法：在2020年3月至2021年5月之间，财务激励措施被嵌入到凯恩斯性健康服务机构建立的以人为本的丙型肝炎护理模式中。自我报告注射药物经验的服务客户获得了AUD20现金奖励，用于丙型肝炎检测，治疗开始，治疗完成,并测试治愈。描述性统计用于描述激励模型中丙型肝炎护理的保留。将它们与干预前11个月提供的护理标准进行比较。
结果：共有121名客户获得了丙型肝炎检测（抗体或RNA）的财务奖励。28个客户是丙型肝炎RNA阳性，其中92%(24/28)开始治疗，75%（21/28）完成治疗，68%(19/28)获得持续病毒学应答(SVR)。确诊为丙型肝炎的患者开始治疗的比例有所改善(86%与75%），完成治疗(75%vs.40%)，并实现了SVR(68%与17%)与干预前比较期相比。
结论：在这项研究中，财政激励措施改善了注射药物者在丙型肝炎护理中的参与度和保留率，该护理模式采用了以人为本和灵活的方法。
方法：在2020年3月至2021年5月之间，财务激励措施被嵌入到凯恩斯性健康服务机构建立的以人为本的丙型肝炎护理模式中。自我报告注射药物经验的服务客户获得了AUD20现金奖励，用于丙型肝炎检测，治疗开始，治疗完成,并测试治愈。描述性统计用于描述激励模型中丙型肝炎护理的保留。将它们与干预前11个月提供的护理标准进行比较。
结果：共有121名客户获得了丙型肝炎检测（抗体或RNA）的财务奖励。28个客户是丙型肝炎RNA阳性，其中92%(24/28)开始治疗，75%（21/28）完成治疗，68%(19/28)获得持续病毒学应答(SVR)。确诊为丙型肝炎的患者开始治疗的比例有所改善(86%与75%），完成治疗(75%vs.40%)，并实现了SVR(68%与17%)与干预前比较期相比。
结论：在这项研究中，财政激励措施改善了注射药物者在丙型肝炎护理中的参与度和保留率，该护理模式采用了以人为本和灵活的方法。
